From the test tube to the patient, we are looking at new, inventive ways to move our product candidates efficiently through the development process in an effort to get new products into the clinic.
At Antagen, we have recombinant protein based vaccines in preclinical development. The vaccines target influenza, rabies, and HPV infection in Asian populations as well as the U.S. population.
We have developed High-Performance mammalian cell lines expressing human serum albumin, second-generation Erythropoietin (EPO), and anti-rabies antibodies. We are seeking partnership with potential investors or pharmaceutical companies to commercialize these biological products.
We are in an early development stage of drugs targeting autoimmune diseases, cancer, Age-Related Macular Degeneration and Diabetes-Associated Retinal Atrophy.
More are under way.
Please feel welcome to contact us for additional information